DCEG News Updates
The latest news and research findings from the Division of Cancer Epidemiology and Genetics.
-
Translational Research Fulfilling the Promise of Genome-Wide Association Studies
Newsletter article discusses examples of the use of genome-wide association studies in translational cancer research
-
Lindsay Morton: Making the Most of Consortia
In almost all of her research, Lindsay M. Morton, Ph.D., has used either formal consortia or extensive networks of scientific collaborators in the search for clues to the causes of cancer. A tenure-track investigator in DCEG’s Radiation Epidemiology Branch (REB), Dr. Morton has focused her research on areas of cancer epidemiology that require large numbers of subjects: rare outcomes, histologic subtypes, and gene-environment interactions. July 2013 Linkage Newsletter
-
Tenure-Track Investigators Develop New Methods for Genetic Analyses
Tenure-Track Investigators Develop New Methods for Genetic Analyses, March 2013 Linkage
-
Understanding the Risks of Medical Radiation
DCEG investigators in the Radiation Epidemiology Branch led new studies that shed further light on cancer risks related to low-dose diagnostic and screening procedures and to high-dose radiation therapy. March 2013 Linkage newsletter
-
Margaret Tucker Appointed as DCEG Acting Director
Margaret Tucker Appointed as DCEG Acting Director, December 2012 Linkage Newsletter
-
Joseph Fraumeni's Contributions to the Scientific Literature
Joseph Fraumeni's Contributions to the Scientific Literature - December 2012 Linkage Newsletter
-
Reflections on the Past and Future of Epidemiology
DCEG was privileged to hold a panel discussion titled Cancer Epidemiology over the Last Half-century and Thoughts on the Future, featuring Dr. Joseph F. Fraumeni, Jr., and Dr. David Schottenfeld, University of Michigan, co-editors of multiple editions of the indispensable textbook Cancer Epidemiology and Prevention. Dr. Robert N. Hoover, Director of DCEG’s Epidemiology and Biostatistics Program, moderated the discussion and posed questions on the major influences that affected the careers of Drs. Fraumeni and Schottenfeld, the key contributors and seminal discoveries in the field of cancer epidemiology, and advice for young epidemiologists. December 2012 Linkage Newsletter
-
The Public Health Impact of DCEG Research
The Public Health Impact of DCEG Research - December 2012 Linkage newsletter
-
From Early Research Themes to the Present
For a majority of scientific themes under study across the Division, Dr. Joseph F. Fraumeni, Jr. conducted seminal work showing the promise of that particular line of research for yielding clues to cancer etiology and prevention. November 2012 Linkage newsletter
-
Legend for Fig 1: Hereditary Multicancer Syndrome
Legend for Fig 1: Hereditary Multicancer Syndrome
-
How a Hereditary Multicancer Syndrome Was Discovered
Li-Fraumeni Syndrome (LFS) is a rare, inherited disorder which leads to a higher risk of certain cancers. NCI has evaluated families with LFS since the syndrome was first recognized in 1969 by Dr. Fred Li and Dr. Joseph Fraumeni. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration. November 2012 Linkage newsletter
-
Impact of Publications Fig1 longdesc
Impact of Publications Fig1 longdesc
-
Measuring the Impact of Publications by Joseph Fraumeni
Several indices have been developed as benchmarks to estimate the overall impact of a scientist’s work. The two most commonly used are the Thomson Reuters Web of Knowledge Science Citation Index (SCI) and the h-index. By any of these measures, the contributions of Joseph F. Fraumeni, Jr., M.D., are remarkable. December 2012 Linkage Newsletter.
-
Joseph Fraumeni: A 50-Year Legacy of Cancer Research
In July 2012, Joseph F. Fraumeni, Jr., M.D., reached a career milestone of 50 years at NCI. He marked this anniversary by stepping down as Director of DCEG, while continuing to serve as a senior investigator and advisor at NCI and NIH. December 2012 issue of Linkage newsletter.
-
DCEG News Article: The DES Follow-Up Study
Newsletter description of the follow-up study on diethylstilbestrol (DES), with history of events and timeline.
-
Unraveling Genetic Susceptibility to Melanoma
Kevin Brown and colleagues used whole-genome sequencing to identify a novel, recurrent mutation in MITF, a familial and sporadic melanoma predisposition gene.
-
Women with BRCA1 and BRCA2 mutations survive ovarian cancer at higher rates than those without mutations
Results from an multi-center study provides strong evidence that women with ovarian cancer who had variants in BRCA1 and BRCA2 were more likely to survive in the five years following diagnosis.
-
Women exposed to DES in the womb face increased cancer risk
Daughters of women who had been given DES, the first synthetic form of estrogen, during pregnancy found exposure to the drug in utero was associated with many reproductive problems and increased risk of certain cancers and pre-cancerous conditions.
-
NIH study finds two doses of HPV vaccine may be as protective as full course
Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up.